(NASDAQ:MLTX) MoonLake Immunotherapeutics Earnings Beat By $0.05
Fundamentals
MoonLake Immunotherapeutics (NASDAQ: MLTX) reported third quarter EPS of $-0.18, $0.05 better than the analyst estimate of $-0.23. Revenue for the quarter came in at $0 versus the consensus estimate of $0.
MoonLake Immunotherapeutics's stock price closed at $37.40. It is down -35.10% in the last 3 months and up 317.77% in the last 12 months.
Technical Analysist
MoonLake Immunotherapeutics has a market capitalization of $2.16 billion. MLTX is trading in the middle of its 52-week range and above its 200-day simple moving average.
What does this mean?
Investors are still evaluating the share price, but the stock still appears to have some upward momentum. This is a positive sign for the stock's future value.
MoonLake Immunotherapeutics (NASDAQ: MLTX) reported third quarter EPS of $-0.18, $0.05 better than the analyst estimate of $-0.23. Revenue for the quarter came in at $0 versus the consensus estimate of $0.
MoonLake Immunotherapeutics's stock price closed at $37.40. It is down -35.10% in the last 3 months and up 317.77% in the last 12 months.
Technical Analysist
MoonLake Immunotherapeutics has a market capitalization of $2.16 billion. MLTX is trading in the middle of its 52-week range and above its 200-day simple moving average.
What does this mean?
Investors are still evaluating the share price, but the stock still appears to have some upward momentum. This is a positive sign for the stock's future value.
⭐⭐⭐ Sign Up for Free ⭐⭐⭐
1) Download our Mobile App >>
Android: dexwirenews.com/APP
Apple: dexwirenews.com/iOS
2) Join our Telegram >> t.me/DEXWireNews
3) Follow @DEXWireNews on Social Media
1) Download our Mobile App >>
Android: dexwirenews.com/APP
Apple: dexwirenews.com/iOS
2) Join our Telegram >> t.me/DEXWireNews
3) Follow @DEXWireNews on Social Media